SAN FRANCISCO, CA USA (UroToday.com) - Dr. Stephanie Anne Holler Howard from department of radiology at Dana-Faber Cancer Institute presented an abstract on whether or not retroperitoneal craniocaudal nodal length (CCNL) or nodal volume (NV) can predict relapse risk in clinical stage I testicular cancer.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
This was a retrospective study of 118 patients with stage I testicular cancer with either more than or equal to 2-years surveillance, or retroperitoneal lymph node dissection with no adjuvant chemotherapy.
Fifty-six percent had nonseminomatous germ-cell tumor (NSGCT) and 44% had seminomatous germ-cell tumor (SGCT). Twenty-one percent (25 out of 118) of patients relapsed: 24% (16 out of 66) for NSGCT and 17% (9 out of 52) for SGCT. 90% of these were at the site of the largest lymph node. On a multivariable logistic regression model adjusting for other potential known risk factors of embryonal predominance (EP) and lymphovascular invasion (LVI), CCNL proved to be an independent risk factor in NSGCT For every 3 mm increase in CCNL; the risk of relapse increased by 52% (odds ratio [OR]=1.52; 95% CI=1.03- 2.25). For patients with SGCT, only the primary tumor size was an independent risk factor for relapse (OR=1.34; 95% CI=1.02-1.75). For patients who had CCNL size > 1.5 cm, they were 4 times more likely to have relapse of disease. Although their findings are valuable, external validation using larger cohorts is needed to further validate if CCNL could provide additional information in management of these patients.
Highlights of a presentation by Stephanie Anne Holler Howard, MD at the 2014 Genitourinary Cancers Symposium - January 30 - February 1, 2014 - San Francisco Marriott Marquis - San Francisco, California USA
Dana-Faber Cancer Institute, Boston, MA USA